These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 30630815)
1. Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. Itkonen MK; Tornio A; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT Drug Metab Dispos; 2019 Apr; 47(4):377-385. PubMed ID: 30630815 [TBL] [Abstract][Full Text] [Related]
2. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Kazmi F; Barbara JE; Yerino P; Parkinson A Drug Metab Dispos; 2015 Apr; 43(4):523-33. PubMed ID: 25595597 [TBL] [Abstract][Full Text] [Related]
3. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535 [TBL] [Abstract][Full Text] [Related]
4. Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Honkalammi J; Niemi M; Neuvonen PJ; Backman JT Clin Pharmacol Ther; 2012 May; 91(5):846-55. PubMed ID: 22472994 [TBL] [Abstract][Full Text] [Related]
5. Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. Itkonen MK; Tornio A; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT Drug Metab Dispos; 2016 Aug; 44(8):1364-71. PubMed ID: 27260150 [TBL] [Abstract][Full Text] [Related]
6. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. Filppula AM; Tornio A; Niemi M; Neuvonen PJ; Backman JT Clin Pharmacol Ther; 2013 Sep; 94(3):383-93. PubMed ID: 23657159 [TBL] [Abstract][Full Text] [Related]
7. Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. Takagi M; Sakamoto M; Itoh T; Fujiwara R Drug Metab Pharmacokinet; 2015 Aug; 30(4):288-94. PubMed ID: 26195223 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of CYP2C8 by Acyl Glucuronides of Gemfibrozil and Clopidogrel: Pharmacological Significance, Progress and Challenges. Shah MB Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139056 [TBL] [Abstract][Full Text] [Related]
9. Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug-Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil. Iga K; Kiriyama A Clin Pharmacokinet; 2024 Jan; 63(1):43-56. PubMed ID: 37921907 [TBL] [Abstract][Full Text] [Related]
10. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Tornio A; Neuvonen PJ; Niemi M; Backman JT Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):83-95. PubMed ID: 27548563 [TBL] [Abstract][Full Text] [Related]
11. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Karonen T; Neuvonen PJ; Backman JT Br J Clin Pharmacol; 2012 Feb; 73(2):257-67. PubMed ID: 21838784 [TBL] [Abstract][Full Text] [Related]
12. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects. Bruderer S; Petersen-Sylla M; Boehler M; Remeňová T; Halabi A; Dingemanse J Br J Clin Pharmacol; 2017 Dec; 83(12):2778-2788. PubMed ID: 28715853 [TBL] [Abstract][Full Text] [Related]
13. A Randomized Study on the Bioequivalence of Desloratadine in Healthy Chinese Subjects and the Association of Different Metabolic Phenotypes With UGT2B10 and CYP2C8 Genotypes. Niu S; Li Y; Dong W; Xia L; Shen T; Wang J; Wang Q; Zhang T; Zhang M; Liu G; Guo D; Fang Y Curr Drug Metab; 2020; 21(13):1031-1039. PubMed ID: 33109037 [TBL] [Abstract][Full Text] [Related]
14. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Aquilante CL; Kosmiski LA; Bourne DW; Bushman LR; Daily EB; Hammond KP; Hopley CW; Kadam RS; Kanack AT; Kompella UB; Le M; Predhomme JA; Rower JE; Sidhom MS Br J Clin Pharmacol; 2013 Jan; 75(1):217-26. PubMed ID: 22625877 [TBL] [Abstract][Full Text] [Related]
15. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Honkalammi J; Niemi M; Neuvonen PJ; Backman JT Drug Metab Dispos; 2011 Oct; 39(10):1977-86. PubMed ID: 21778352 [TBL] [Abstract][Full Text] [Related]
16. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Karonen T; Filppula A; Laitila J; Niemi M; Neuvonen PJ; Backman JT Clin Pharmacol Ther; 2010 Aug; 88(2):223-30. PubMed ID: 20592724 [TBL] [Abstract][Full Text] [Related]
17. Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. Tornio A; Niemi M; Neuvonen PJ; Backman JT Eur J Clin Pharmacol; 2007 May; 63(5):463-9. PubMed ID: 17333159 [TBL] [Abstract][Full Text] [Related]
18. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. Shitara Y; Hirano M; Sato H; Sugiyama Y J Pharmacol Exp Ther; 2004 Oct; 311(1):228-36. PubMed ID: 15194707 [TBL] [Abstract][Full Text] [Related]
19. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Tornio A; Neuvonen PJ; Backman JT Eur J Clin Pharmacol; 2006 Aug; 62(8):645-51. PubMed ID: 16832679 [TBL] [Abstract][Full Text] [Related]
20. Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil. Jenkins SM; Zvyaga T; Johnson SR; Hurley J; Wagner A; Burrell R; Turley W; Leet JE; Philip T; Rodrigues AD Drug Metab Dispos; 2011 Dec; 39(12):2421-30. PubMed ID: 21911547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]